Traws Pharma (TRAW) Net Equity Issued and Repurchased (2015 - 2026)
Traws Pharma (TRAW) posted quarterly Net Equity Issued and Repurchased of $1.9 million for Q1 2026, up 1454.92% year-over-year from $122000.0 in Q1 2025, and down 9.1% quarter-over-quarter from $2.1 million in Q4 2025.
Traws Pharma (TRAW) Net Equity Issued and Repurchased (2015 - 2026) Analysis & Trends
Traws Pharma (TRAW) has reported Net Equity Issued and Repurchased for 9 consecutive years, with $1.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Equity Issued and Repurchased rose 1454.92% year-over-year to $1.9 million; the TTM figure through Mar 2026 stood at $7.4 million (up 11.47% YoY), while the FY2025 annual figure was $5.6 million, down 72.06% from the prior year.
- Net Equity Issued and Repurchased slipped to $1.9 million in Q1 2026 per TRAW's latest filing, from $2.1 million in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $6.0 million in Q4 2024 and bottomed at $116000.0 in Q3 2025.
- Historically, Net Equity Issued and Repurchased has averaged $1.8 million across 4 years, with a median of $1.2 million in 2022.
- Annual changes were most pronounced in 2022 — Net Equity Issued and Repurchased slumped 98.58% — and 2026, when it jumped 1454.92%.
- Traws Pharma's Net Equity Issued and Repurchased stood at $500000.0 in 2022, then soared by 1095.6% to $6.0 million in 2024, then slumped by 65.09% to $2.1 million in 2025, then slipped by 9.1% to $1.9 million in 2026.
- Business Quant data shows TRAW's Net Equity Issued and Repurchased at $1.9 million in Q1 2026, $2.1 million in Q4 2025, and $116000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Traws Pharma | 5.66 Mn | 639,491.99 | - | 119,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.90 Mn |
| Mar 31, 2026 | 1.90 Mn |
| Dec 31, 2025 | 2.09 Mn |
| Dec 31, 2025 | 2.09 Mn |
| Sep 30, 2025 | 116,000.00 |
| Sep 30, 2025 | 116,000.00 |
| Jun 30, 2025 | 3.26 Mn |
| Jun 30, 2025 | 3.26 Mn |
| Mar 31, 2025 | 122,000.00 |
| Mar 31, 2025 | 122,000.00 |
| Dec 31, 2024 | 5.98 Mn |
| Dec 31, 2024 | 5.98 Mn |
| Jun 30, 2022 | 500,000.00 |
| Jun 30, 2022 | 500,000.00 |
| Mar 31, 2022 | 500,000.00 |
| Mar 31, 2022 | 500,000.00 |
| Dec 31, 2021 | -50,000.00 |
| Dec 31, 2021 | -50,000.00 |
| Sep 30, 2021 | 500,000.00 |
| Sep 30, 2021 | 500,000.00 |